News & Events about Landos Biopharma Inc.
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the ...
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (Landos or the Company), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of ...
Globe Newswire
2 months ago
On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming WeeksNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today ...
Globe Newswire
5 months ago
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On ...
Landos Biopharma, Inc. (NASDAQ:LABP Get Rating) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 133,200 shares, an increase of 16.4% from the June 30th total of 114,400 shares. Based on an average daily volume of ...